Development of daptomycin for Gram-positive infections

Development of daptomycin for gram-positive infections.

Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections.

Infections caused by drug-resistant pathogens are on the rise. Daptomycin, a cyclic lipopeptide with activity against most Gram-positive pathogens, including vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus, is a newly US-FDA approved antimicrobial for complicated skin and skin structure infections (cSSSI). Daptomycin has a unique mechanism of action that results...

Prescribing trends with daptomycin (cubicin) for the treatment of gram-positive infections.

The injectable agent daptomycin, when prescribed according to approved guidelines, can be a welcome option for treating some multiresistant, gram-positive infections that have become increasingly prevalent.

Daptomycin for the treatment of major gram-positive infections after cardiac surgery

BACKGROUND Infection is a main cause of morbidity and mortality after heart surgery, with multi-resistant pathogens increasingly representing a challenge. Daptomycin provides bactericidal activity against gram-positive organisms that are resistant to standard treatment including vancomycin. METHODS A cohort of cardiac surgical patients, treated with daptomycin for major infection at two terti...

Clinical Experience with Daptomycin for the Treatment of Gram-positive Infections in Children and Adolescents

BACKGROUND This subgroup analysis of the European Cubicin Outcomes Registry Experience evaluated the safety and effectiveness of daptomycin in children and adolescent patients (<18 years). METHODS Clinical outcomes at the end of therapy were assessed as success (cured or improved), failure or nonevaluable. Safety was assessed for up to 30 days post treatment. RESULTS Eighty-one children and...